Yves Benhamou

13.1k total citations · 2 hit papers
101 papers, 8.2k citations indexed

About

Yves Benhamou is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Yves Benhamou has authored 101 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Epidemiology, 86 papers in Hepatology and 21 papers in Infectious Diseases. Recurrent topics in Yves Benhamou's work include Hepatitis C virus research (84 papers), Hepatitis B Virus Studies (72 papers) and Liver Disease Diagnosis and Treatment (62 papers). Yves Benhamou is often cited by papers focused on Hepatitis C virus research (84 papers), Hepatitis B Virus Studies (72 papers) and Liver Disease Diagnosis and Treatment (62 papers). Yves Benhamou collaborates with scholars based in France, United States and Germany. Yves Benhamou's co-authors include Thierry Poynard, Frédéric Charlotte, Vlad Ratziu, Françoise Imbert‐Bismut, Vincent Thibault, Christine Katlama, Vincent Di Martino, Marie Bochet, Laurence Piéroni and P Opolon and has published in prestigious journals such as The Lancet, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Yves Benhamou

99 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

2001 1.1k citations Françoise Imbert‐Bismut, Vlad Ratziu et al. The Lancet profile →
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

1999 985 citations Yves Benhamou, Marie Bochet et al. Hepatology profile →

Peers

Countries citing papers authored by Yves Benhamou

Since Specialization

Citations

This map shows the geographic impact of Yves Benhamou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Benhamou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Benhamou more than expected).

Fields of papers citing papers by Yves Benhamou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yves Benhamou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Benhamou. The network helps show where Yves Benhamou may publish in the future.

Co-authorship network of co-authors of Yves Benhamou

This figure shows the co-authorship network connecting the top 25 collaborators of Yves Benhamou. A scholar is included among the top collaborators of Yves Benhamou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yves Benhamou. Yves Benhamou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: “APRI c’est fini ?” 2014 ·Clinics and Research in Hepatology and Gastroenterology ·Hugo Perazzo, Raluca Pais, M. Munteanu, Yen Ngo, Denis Monneret, Françoise Imbert‐Bismut, J. Moussalli, Pascal Lebray, Yves Benhamou, Dominique Thabut, Vlad Ratziu, (unknown), Thierry Poynard	5
2	Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: A retrospective repeated liver biopsy analysis 2011 ·Journal of Hepatology ·Patrick Ingiliz, Marc‐Antoine Valantin, Paul Preziosi, Laetitia Finzi, R. Pais, Larysa Fedchuk, Stéphanie Dominguez, Christine Katlama, Thierry Poynard, Yves Benhamou	13
3	Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection 2010 ·Journal of Hepatology ·Michael P. Manns, Marc Bourlière, Yves Benhamou, Stanislas Pol, Maurizio Bonacini, C. Trépo, David W. Wright, Thomas Berg, José Luís Calleja, Peter W. White, Jerry O. Stern, Gerhard Steinmann, Chan‐Loi Yong, George Kukolj, (unknown), Wulf O. Boecher	89
4	Hirsch Index and Truth Survival in Clinical Research 2010 ·PLoS ONE ·Thierry Poynard, Dominique Thabut, M. Munteanu, Vlad Ratziu, Yves Benhamou, Olivier Deckmyn	9
5	Safety and Antiviral Activity of Tmc435350 in Treatment-name Genotype 1 Hcv-infected Patients 2008 ·Hepatology ·Michael P. Manns, Yves Horsmans, Hendrik W. Reesink, Christophe Moreno, Thomas Berg, Yves Benhamou, Geoffrey Dusheiko, Robert Flisiak, Paul Meyvisch, Oliver Lenz, Kenneth Simmen, René Verloes	3
6	Assessment of liver fibrosis: Noninvasive means 2008 ·Saudi Journal of Gastroenterology ·Thierry Poynard, Rachel Morra, Patrick Ingiliz, Françoise Imbert‐Bismut, Dominique Thabut, Djamila Messous, M. Munteanu, Julien Massard, Yves Benhamou, Vlad Ratziu	31
7	Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy # 2008 ·Hepatology ·Patrick Ingiliz, Marc‐Antoine Valantin, Claudine Duvivier, Fadia Medja, Stéphanie Dominguez, Frédéric Charlotte, Roland Tubiana, Thierry Poynard, Christine Katlama, Anne Lombès, Yves Benhamou	106
8	The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption 2008 ·European Journal of Gastroenterology & Hepatology ·Françoise Imbert‐Bismut, Sylvie Naveau, Rachel Morra, M. Munteanu, Vlad Ratziu, Annie Abella, Djamila Messous, Dominique Thabut, Yves Benhamou, Thierry Poynard	12
9	Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel 2007 ·AIDS ·Vincent Soriano, Massimo Puoti, Mark Sulkowski, Antonietta Cargnel, Yves Benhamou, Marion G. Peters, Stefan Mauss, Norbert Bräu, Angelos Hatzakis, Stanislas Pol, Juergen Rockstroh	256
10	Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients 2006 ·AIDS ·Stéphanie Dominguez, Jade Ghosn, Marc‐Antoine Valantin, (unknown), Anne Simon, Philippe Bonnard, Éric Caumes, Gilles Pialoux, Yves Benhamou, Vincent Thibault, Christine Katlama	85
11	Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C†‡ 2005 ·Hepatology ·Markus Reiser, Holger Hinrichsen, Yves Benhamou, H. W. Reesink, Heiner Wedemeyer, C. Avendaño, (unknown), Chan‐Loi Yong, Gerhard Nehmiz, Gerhard Steinmann	121
12	Antiretroviral Therapy and HIV/Hepatitis B Virus Coinfection 2004 ·Clinical Infectious Diseases ·Yves Benhamou	47
13	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients 2004 ·Gastroenterology ·Holger Hinrichsen, Yves Benhamou, Heiner Wedemeyer, Markus Reiser, Roel Sentjens, José Luís Calleja, Xavier Forns, Andreas Erhardt, (unknown), Ricardo L. Chaves, Chan‐Loi Yong, Gerhard Nehmiz, Gerhard Steinmann	233
14	Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients 2003 ·AIDS ·Robert P. Myers, Yves Benhamou, Françoise Imbert‐Bismut, Vincent Thibault, Marie Bochet, Frédéric Charlotte, Vlad Ratziu, François Bricaire, Christine Katlama, Thierry Poynard	155
15	Quelles sont les indications du traitement dans l'hépatite C aiguë ? 2002 ·Gastroentérologie Clinique et Biologique ·Robert P. Myers, Corinne Regimbeau, J. Moussalli, Vlad Ratziu, Vincent Di Martino, Dominique Thabut, Brigitte Bernard, Yves Benhamou, Thierry Poynard	2
16	Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study breakdown → 2001 ·The Lancet ·Françoise Imbert‐Bismut, Vlad Ratziu, Laurence Piéroni, Frédéric Charlotte, Yves Benhamou, Thierry Poynard	1110
17	Natural history of HCV infection 2000 ·Best Practice & Research Clinical Gastroenterology ·Thierry Poynard, Vlad Ratziu, Yves Benhamou, Pierre Opolon, P. Cacoub, Pierre Bédossa	86
18	Cryptosporidium parvumInfection in Suckling Rats: Impairment of Mucosal Permeability and Na+-Glucose Cotransport 1999 ·Experimental Parasitology ·C. Capet, (unknown), Jean François Huneau, Denis Magne, René Lai–Kuen, Viviane Tricottet, Yves Benhamou, Daniel Tomé, J.G. Gobert	22
19	Kinetics of mucosal ileal gamma-interferon response during cryptosporidiosis in immunocompetent neonatal mice 1996 ·Parasitology Research ·Nathalie Kapel, Yves Benhamou, (unknown), Denis Magne, P Opolon, Jean‐Gérard Gobert, (unknown)	40
20	Inefficacy of intestinal secretory immune response to Cryptosporidium in acquired immunodeficiency syndrome 1995 ·Gastroenterology ·Yves Benhamou, Nathalie Kapel, (unknown), (unknown), D. Meillet, Denis Magne, Martine Raphaël, M Gentilini, (unknown), Jean‐Gérard Gobert	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact